FYI from the NHLBI Index

January 2012: Vol. 12, Issue 3
Research and Resources

NHLBI Research Initiatives

• Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)
• NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (R01)
• Virtual Reality Technologies for Research and Education in Obesity and Diabetes (R41/R42)
• Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34)

Need More Information?

NHLBI Research Initiatives

From time to time, the NHLBI invites investigators to submit grant applications or contract proposals for specific research programs. We are soliciting applications for the new programs described below. Please visit the URL listed with each program to obtain information about application dates and deadlines. For full details of these and other current research initiatives, visit www.nhlbi.nih.gov/funding/inits/index.htm.

Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)

• Initiative Number: RFA-HL-12-022
• Objective: Conduct Phase II clinical therapeutic trials that have the potential to advance development of novel therapies for a lung disease or a cardiopulmonary disorder of sleep.

NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (R01)

• Initiative Number: PAR-12-010 and PAR-12-011
• Objective: Support an expansion of the scope of already approved and funded R01 projects involving smoking and tobacco products.

Virtual Reality Technologies for Research and Education in Obesity and Diabetes (R41/R42)

• Initiative Number: RFA-HL-12-020 and RFA-HL-12-024
• Objective: Capitalize on the unique capabilities of virtual reality technologies to extend the health care and learning environments for patients with obesity and diabetes.

Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34)

• Initiative Number: RFA-HL-12-023
• Objective: Encourage the planning and development of feasible and well-designed multicenter clinical trials focused on rare hemostatic and thrombotic disorders.

Need More Information?

We are always interested in receiving comments and suggestions from the community. If you or your organizations have questions for me or for the Institute, please contact me at shurinsb@nhlbi.nih.gov or Dr. Carl Roth at rothc@nhlbi.nih.gov.

Susan B. Shurin, M.D.
Acting Director, NHLBI

For information on specific issues, the following contacts may be helpful:

For health related questions and publications, please contact the trained information specialists at the NHLBI Information Center (NHLBIinfo@nhlbi.nih.gov) or write to the Information Center at P.O. Box 30105, Bethesda, MD 20824-0105.

For communications pertaining to NHLBI policies and priorities, contact the NHLBI Office of Public Liaison, (nhlbi.listens@nih.gov).

For additional information regarding NHLBI events, consult the references provided or NHLBI Calendar. Most other NIH Institutes and Centers also maintain calendars on their websites. Links to their Web pages are at NIH Institutes, Centers, and Offices.

For Web related matters pertaining to the online version of the FYI from the NHLBI, contact the FYI from the NHLBI's Web Editor.

Please send us your feedback, comments, and questions by using the appropriate link on the page, Contact the NHLBI.

Note to users of screen readers and other assistive technologies: please report your problems here.